We then challenged the SMARCA4-knockdown cells to a variety of chemotherapeutic agents, focusing on those that have been evaluated clinically in the treatment of pancreatic cancer [22]. This evidence concerns the gene SMARCA4 and familial pancreatic carcinoma.